News and analysis on disease research and diagnostics.
The company believes its tests can already help oncologists better assess post-surgery risk, though prospective validation would be necessary for broad claims.
The 20-minute PCR-based test had near complete agreement with lab-based testing.
Ravgen has alleged that several leading NGS-based non-invasive prenatal testing and oncology assays infringe two patents held by the firm.
The test originally received Emergency Use Authorization in February for the detection of SARS-CoV-2 nucleic acid in upper and lower respiratory specimens.
Patients who underwent SLCO1B1 testing were able to lower their cholesterol levels similarly to those who did not, indicating that testing does not cause harm.
